[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
暂无分享,去创建一个
A. Schaefer-Schuler | M. Bartholomä | G. Franssen | J. Nagarajah | S. Maus | S. Ezziddin | F. Rosar | Y. Derks | B. Privé | C. Burgard | Sven Petto | Fadi Khreish
[1] Steffie M. B. Peters,et al. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[2] A. Afshar-Oromieh,et al. Radiolabeled PSMA Inhibitors , 2021, Cancers.
[3] M. Schreckenberger,et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[4] A. Drzezga,et al. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients , 2021, The Journal of Nuclear Medicine.
[5] A. Kishan,et al. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. , 2021, European urology oncology.
[6] T. Holland-Letz,et al. Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[7] R. Boellaard,et al. The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals , 2020, The Journal of Nuclear Medicine.
[8] Kyung-Han Lee,et al. 89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression , 2020, Journal of Nuclear Medicine.
[9] Joon-Kee Yoon,et al. Current Perspectives on 89Zr-PET Imaging , 2020, International journal of molecular sciences.
[10] F. Mottaghy,et al. Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients , 2020, The Journal of Nuclear Medicine.
[11] P. Carroll,et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.
[12] A. Buck,et al. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer , 2019, Nuklearmedizin.
[13] D. Murphy,et al. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. , 2018, The Urologic clinics of North America.
[14] Sören Mattsson,et al. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms , 2017, EJNMMI Research.
[15] O. Boerman,et al. 89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry , 2017, Bioconjugate chemistry.
[16] Steven P. Rowe,et al. PSMA Ligands for PET Imaging of Prostate Cancer , 2017, The Journal of Nuclear Medicine.
[17] Matthias Eiber,et al. 177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.
[18] H. Kauczor,et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[19] Bernd J. Krause,et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[20] B. Hadaschik,et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[21] U. Haberkorn,et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[22] U. Haberkorn,et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.
[23] U. Haberkorn,et al. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Tim Holland-Letz,et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.
[25] Christoph Hoeschen,et al. Electron specific absorbed fractions for the adult male and female ICRP/ICRU reference computational phantoms , 2012, Physics in medicine and biology.
[26] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[27] U. Haberkorn,et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.